CONTEXT: Commercial announcement of a tie up between pharma and a real-word data provider to drive improvements in cancer treatments.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “”With the support of the FDA, Kite and many others, COTA is helping to pioneer the use of RWD in clinical research with the ultimate goal of accelerating clinical development, reducing healthcare costs, and helping cancer patients live longer, healthier lives.””
2. “COTA provides comprehensive and diverse cancer RWD to leading life sciences and healthcare provider organizations that are caring and developing treatments for patients living with a wide range of cancers.”
3. “As RWD is increasingly applied in clinical development, COTA’s customized data sets can help increase patient diversity in clinical trials; expand indications of already approved drugs; replace the traditional standard-of-care or placebo group via a RWD-powered synthetic control arm; and empower life sciences companies to make faster decisions on their pipeline.”
4. “Offering the highest quality oncology real-world data from leading academic and community-based cancer centers and an advanced analytics platform, COTA partners with leading life sciences companies, providers, and payers to ensure that everyone touched by cancer has a clear path to the right care.”
5. “To learn more about COTA and how to fast-track improvements in cancer care and treatment with comprehensive and diverse real-world data and analytics, visit .”